fasudil has been researched along with Diabetic Angiopathies in 5 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
Excerpt | Relevance | Reference |
---|---|---|
" Further, perivascular and myocardial fibrosis, arterial intimal thickening were assessed by histology, and capillary density, nitrotyrosine and ROCK1/2 expressions were evaluated by immunohistochemical staining." | 3.79 | Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation. ( Edgley, AJ; Fujii, Y; Jenkins, MJ; Joshi, M; Kelly, DJ; Pearson, JT; Schwenke, DO; Shirai, M; Sonobe, T; Tsuchimochi, H; Umetani, K; Waddingham, MT; Yoshimoto, M, 2013) |
"Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mishra, RK | 1 |
Alokam, R | 1 |
Sriram, D | 1 |
Yogeeswari, P | 1 |
Pearson, JT | 1 |
Jenkins, MJ | 1 |
Edgley, AJ | 1 |
Sonobe, T | 1 |
Joshi, M | 1 |
Waddingham, MT | 1 |
Fujii, Y | 1 |
Schwenke, DO | 1 |
Tsuchimochi, H | 1 |
Yoshimoto, M | 1 |
Umetani, K | 1 |
Kelly, DJ | 1 |
Shirai, M | 1 |
Li, T | 1 |
Yang, GM | 1 |
Zhu, Y | 1 |
Wu, Y | 1 |
Chen, XY | 1 |
Lan, D | 1 |
Tian, KL | 1 |
Liu, LM | 1 |
Nuno, DW | 1 |
Lamping, KG | 1 |
Arita, R | 1 |
2 reviews available for fasudil and Diabetic Angiopathies
Article | Year |
---|---|
Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomyopathies; Diabetes Complicat | 2013 |
[Mechanism of diabetes-induced microvascular damage and therapeutic potential of ROCK inhibition].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Angiopathies; Diabetic Retinopathy; | 2011 |
3 other studies available for fasudil and Diabetic Angiopathies
Article | Year |
---|---|
Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Coronary Angiography; Coronary Circulation; | 2013 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |
The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2010 |